Bulk Manufacturer of Controlled Substances Application: Patheon Pharmaceuticals, Inc., 23067 [2017-10238]
Download as PDF
<![CDATA[
23067
Federal Register / Vol. 82, No. 96 / Friday, May 19, 2017 / Notices
[Docket No. DEA–392]
Morrissette Drive, Springfield, Virginia
22152.
SUPPLEMENTARY INFORMATION: The
Attorney General has delegated his
authority under the Controlled
Substances Act to the Administrator of
the Drug Enforcement Administration
(DEA), 28 CFR 0.100(b). Authority to
exercise all necessary functions with
respect to the promulgation and
implementation of 21 CFR part 1301,
incident to the registration of
manufacturers, distributors, dispensers,
importers, and exporters of controlled
substances (other than final orders in
connection with suspension, denial, or
revocation of registration) has been
redelegated to the Assistant
Administrator of the DEA Diversion
Control Division (‘‘Assistant
Administrator’’) pursuant to section 7 of
28 CFR part 0, appendix to subpart R.
In accordance with 21 CFR
1301.33(a), this is notice that on
December 2, 2016, Patheon
Pharmaceuticals, Inc., 2110 E. Galbraith
Road, Cincinnati, Ohio 45237 applied to
be registered as a bulk manufacturer of
gamma hydroxybutyric acid (2010) a
basic class of controlled substance listed
in schedule I.
The company plans to manufacture
the listed controlled substance for
product development.
Bulk Manufacturer of Controlled
Substances Application: Patheon
Pharmaceuticals, Inc.
Dated: May 15, 2017.
Louis J. Milione,
Assistant Administrator.
Administrator’’) pursuant to section 7 of
28 CFR part 0, appendix to subpart R.
In accordance with 21 CFR
1301.33(a), this is notice that on March
21, 2017, Insys Manufacturing, LLC,
2700 Oakmont Drive, Round Rock,
Texas 78665 applied to be registered as
a bulk manufacturer of the following
basic classes of controlled substances:
Controlled substance
Schedule
Marihuana (7360) .........................
Tetrahydrocannabinols (7370) .....
I
I
The company plans to manufacture
bulk synthetic active pharmaceutical
ingredients (APIs) for product
development and distribution to its
customers. No other activity for these
drug codes is authorized for this
registration.
Dated: May 15, 2017.
Louis J. Milione,
Assistant Administrator.
[FR Doc. 2017–10230 Filed 5–18–17; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[FR Doc. 2017–10238 Filed 5–18–17; 8:45 am]
ACTION:
Notice of application.
BILLING CODE 4410–09–P
Registered bulk manufacturers of
the affected basic class, and applicants
therefore, may file written comments on
or objections to the issuance of the
proposed registration in accordance
with 21 CFR 1301.33(a) on or before July
18, 2017.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DRW 8701
DATES:
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–392]
Registered bulk manufacturers of
the affected basic class, and applicants
therefore, may file written comments on
or objections to the issuance of the
proposed registration in accordance
with 21 CFR 1301.33(a) on or before July
18, 2017.
DATES:
Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DRW, 8701
Morrissette Drive, Springfield, Virginia
22152.
ADDRESSES:
The
Attorney General has delegated his
authority under the Controlled
Substances Act to the Administrator of
the Drug Enforcement Administration
(DEA), 28 CFR 0.100(b). Authority to
exercise all necessary functions with
respect to the promulgation and
implementation of 21 CFR part 1301,
incident to the registration of
manufacturers, distributors, dispensers,
importers, and exporters of controlled
substances (other than final orders in
connection with suspension, denial, or
revocation of registration) has been
redelegated to the Assistant
Administrator of the DEA Diversion
Control Division (‘‘Assistant
Administrator’’) pursuant to section 7 of
28 CFR part 0, appendix to subpart R.
In accordance with 21 CFR
1301.33(a), this is notice that on March
3, 2017, Eli-Elsohly Laboratories,
Mahmoud A. Elsohly Ph. D., 5
Industrial Park Drive, Oxford,
Mississippi 38655 applied to be
registered as a bulk manufacturer of the
following basic classes of controlled
substances:
SUPPLEMENTARY INFORMATION:
Bulk Manufacturer of Controlled
Substances Application: Eli-Elsohly
Laboratories
ACTION:
Notice of application.
asabaliauskas on DSK3SPTVN1PROD with NOTICES
Controlled substance
Drug code
Marihuana Extract ...........................................................................................................................................................
Marihuana ........................................................................................................................................................................
Tetrahydrocannabinols ....................................................................................................................................................
Dihydromorphine .............................................................................................................................................................
Amphetamine ...................................................................................................................................................................
Methamphetamine ...........................................................................................................................................................
Cocaine ............................................................................................................................................................................
Codeine ...........................................................................................................................................................................
Dihydrocodeine ................................................................................................................................................................
Oxycodone .......................................................................................................................................................................
Hydromorphone ...............................................................................................................................................................
Ecgonine ..........................................................................................................................................................................
Hydrocodone ...................................................................................................................................................................
Morphine ..........................................................................................................................................................................
Thebaine ..........................................................................................................................................................................
VerDate Sep<11>2014
19:15 May 18, 2017
Jkt 241001
PO 00000
Frm 00115
Fmt 4703
Sfmt 4703
E:\FR\FM\19MYN1.SGM
19MYN1
7350
7360
7370
9145
1100
1105
9041
9050
9120
9143
9150
9180
9193
9300
9333
Schedule
I
I
I
I
II
II
II
II
II
II
II
II
II
II
II
]]>Agencies
[Federal Register Volume 82, Number 96 (Friday, May 19, 2017)]
[Notices]
[Page 23067]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-10238]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-392]
Bulk Manufacturer of Controlled Substances Application: Patheon
Pharmaceuticals, Inc.
ACTION: Notice of application.
-----------------------------------------------------------------------
DATES: Registered bulk manufacturers of the affected basic class, and
applicants therefore, may file written comments on or objections to the
issuance of the proposed registration in accordance with 21 CFR
1301.33(a) on or before July 18, 2017.
ADDRESSES: Written comments should be sent to: Drug Enforcement
Administration, Attention: DEA Federal Register Representative/DRW 8701
Morrissette Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: The Attorney General has delegated his
authority under the Controlled Substances Act to the Administrator of
the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority
to exercise all necessary functions with respect to the promulgation
and implementation of 21 CFR part 1301, incident to the registration of
manufacturers, distributors, dispensers, importers, and exporters of
controlled substances (other than final orders in connection with
suspension, denial, or revocation of registration) has been redelegated
to the Assistant Administrator of the DEA Diversion Control Division
(``Assistant Administrator'') pursuant to section 7 of 28 CFR part 0,
appendix to subpart R.
In accordance with 21 CFR 1301.33(a), this is notice that on
December 2, 2016, Patheon Pharmaceuticals, Inc., 2110 E. Galbraith
Road, Cincinnati, Ohio 45237 applied to be registered as a bulk
manufacturer of gamma hydroxybutyric acid (2010) a basic class of
controlled substance listed in schedule I.
The company plans to manufacture the listed controlled substance
for product development.
Dated: May 15, 2017.
Louis J. Milione,
Assistant Administrator.
[FR Doc. 2017-10238 Filed 5-18-17; 8:45 am]
BILLING CODE 4410-09-P
